As of 2026-10-04, the Intrinsic Value of TG Therapeutics Inc (TGTX) is 50.30 USD. This TGTX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 54.29 USD, the upside of TG Therapeutics Inc is -7.40%.
The range of the Intrinsic Value is 31.34 - 123.82 USD
Based on its market price of 54.29 USD and our intrinsic valuation, TG Therapeutics Inc (TGTX) is overvalued by 7.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 31.34 - 123.82 | 50.30 | -7.4% |
| DCF (Growth 10y) | 80.37 - 326.39 | 130.84 | 141.0% |
| DCF (EBITDA 5y) | 46.76 - 61.47 | 54.12 | -0.3% |
| DCF (EBITDA 10y) | 95.71 - 143.62 | 117.92 | 117.2% |
| Fair Value | 72.10 - 72.10 | 72.10 | 32.81% |
| P/E | 28.35 - 80.70 | 52.32 | -3.6% |
| EV/EBITDA | 11.48 - 26.18 | 18.06 | -66.7% |
| EPV | 2.28 - 4.46 | 3.37 | -93.8% |
| DDM - Stable | 26.49 - 124.49 | 75.49 | 39.1% |
| DDM - Multi | 32.56 - 122.66 | 51.91 | -4.4% |
| Market Cap (mil) | 8,310.71 |
| Beta | 0.40 |
| Outstanding shares (mil) | 153.08 |
| Enterprise Value (mil) | 8,573.52 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.85% |
| Cost of Debt | 12.64% |
| WACC | 8.94% |